Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients

Project of the Kyushu University Liver Disease Study Group

Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Akihide Masumoto, Toshihiro Maruyama, Makoto Nakamuta, Munechika Enjoji, Koichi Azuma, Junya Shimono, Hironori Sakai, Shinji Shimoda, Jun Hayashi

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Aim: The aim of the present study was to investigate the association between the length of the treatment period and the cumulative dose of pegylated interferon alpha-2b (peg-IFN alpha-2b) plus ribavirin (RBV) and their effectiveness in the treatment of chronic hepatitis C. Methods: Seven hundred and fifteen patients received peg-IFN alpha-2b plus RBV treatment for 48 weeks and 24 weeks for genotypes 1 (n = 586) and 2 (n = 129), respectively. Results: Sustained virological responses (SVR), defined as serum hepatitis C virus (HCV)-RNA undetectable at 24 weeks after the end of treatment, were 42.4% and 74.4% in genotypes 1 and 2, respectively, on an intention-to-treat analysis. SVR significantly increased with treatment length (4.7%, 36.4%, and 51.8% for < 24 weeks, 24-47 weeks, and 48 weeks, respectively, for genotype 1; and 28.6%, 57.1%, 78.3% for < 12 weeks, 12-23 weeks, and 24 weeks, respectively, for genotype 2). SVR significantly increased with total cumulative treatment dose (21.1%, 36.5%, and 52.9% with < 60%, 60-79%, and ≥ 80% in peg-IFN dose; 29.6%, 51.1%, and 59.2% with < 60%, 60-79%, and ≥ 80% in RBV dose) in genotype 1, although it did not differ significantly for genotype 2. Conclusions: In peg-IFN alpha-2b plus RBV treatment for chronic hepatitis C, it is important to complete the target length of treatment and to continue the target dosage to achieve SVR, especially for genotype 1 patients.

Original languageEnglish
Pages (from-to)1094-1104
Number of pages11
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume23
Issue number7 PT1
DOIs
Publication statusPublished - Jan 1 2008

Fingerprint

Ribavirin
Chronic Hepatitis C
Liver Diseases
Genotype
Therapeutics
Intention to Treat Analysis
peginterferon alfa-2b
Hepacivirus
RNA
Serum

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients : Project of the Kyushu University Liver Disease Study Group. / Furusyo, Norihiro; Kajiwara, Eiji; Takahashi, Kazuhiro; Nomura, Hideyuki; Tanabe, Yuichi; Masumoto, Akihide; Maruyama, Toshihiro; Nakamuta, Makoto; Enjoji, Munechika; Azuma, Koichi; Shimono, Junya; Sakai, Hironori; Shimoda, Shinji; Hayashi, Jun.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 23, No. 7 PT1, 01.01.2008, p. 1094-1104.

Research output: Contribution to journalArticle

Furusyo, Norihiro ; Kajiwara, Eiji ; Takahashi, Kazuhiro ; Nomura, Hideyuki ; Tanabe, Yuichi ; Masumoto, Akihide ; Maruyama, Toshihiro ; Nakamuta, Makoto ; Enjoji, Munechika ; Azuma, Koichi ; Shimono, Junya ; Sakai, Hironori ; Shimoda, Shinji ; Hayashi, Jun. / Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients : Project of the Kyushu University Liver Disease Study Group. In: Journal of Gastroenterology and Hepatology (Australia). 2008 ; Vol. 23, No. 7 PT1. pp. 1094-1104.
@article{744cb10106514a75ba01cdf942bc291b,
title = "Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group",
abstract = "Aim: The aim of the present study was to investigate the association between the length of the treatment period and the cumulative dose of pegylated interferon alpha-2b (peg-IFN alpha-2b) plus ribavirin (RBV) and their effectiveness in the treatment of chronic hepatitis C. Methods: Seven hundred and fifteen patients received peg-IFN alpha-2b plus RBV treatment for 48 weeks and 24 weeks for genotypes 1 (n = 586) and 2 (n = 129), respectively. Results: Sustained virological responses (SVR), defined as serum hepatitis C virus (HCV)-RNA undetectable at 24 weeks after the end of treatment, were 42.4{\%} and 74.4{\%} in genotypes 1 and 2, respectively, on an intention-to-treat analysis. SVR significantly increased with treatment length (4.7{\%}, 36.4{\%}, and 51.8{\%} for < 24 weeks, 24-47 weeks, and 48 weeks, respectively, for genotype 1; and 28.6{\%}, 57.1{\%}, 78.3{\%} for < 12 weeks, 12-23 weeks, and 24 weeks, respectively, for genotype 2). SVR significantly increased with total cumulative treatment dose (21.1{\%}, 36.5{\%}, and 52.9{\%} with < 60{\%}, 60-79{\%}, and ≥ 80{\%} in peg-IFN dose; 29.6{\%}, 51.1{\%}, and 59.2{\%} with < 60{\%}, 60-79{\%}, and ≥ 80{\%} in RBV dose) in genotype 1, although it did not differ significantly for genotype 2. Conclusions: In peg-IFN alpha-2b plus RBV treatment for chronic hepatitis C, it is important to complete the target length of treatment and to continue the target dosage to achieve SVR, especially for genotype 1 patients.",
author = "Norihiro Furusyo and Eiji Kajiwara and Kazuhiro Takahashi and Hideyuki Nomura and Yuichi Tanabe and Akihide Masumoto and Toshihiro Maruyama and Makoto Nakamuta and Munechika Enjoji and Koichi Azuma and Junya Shimono and Hironori Sakai and Shinji Shimoda and Jun Hayashi",
year = "2008",
month = "1",
day = "1",
doi = "10.1111/j.1440-1746.2008.05319.x",
language = "English",
volume = "23",
pages = "1094--1104",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "7 PT1",

}

TY - JOUR

T1 - Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients

T2 - Project of the Kyushu University Liver Disease Study Group

AU - Furusyo, Norihiro

AU - Kajiwara, Eiji

AU - Takahashi, Kazuhiro

AU - Nomura, Hideyuki

AU - Tanabe, Yuichi

AU - Masumoto, Akihide

AU - Maruyama, Toshihiro

AU - Nakamuta, Makoto

AU - Enjoji, Munechika

AU - Azuma, Koichi

AU - Shimono, Junya

AU - Sakai, Hironori

AU - Shimoda, Shinji

AU - Hayashi, Jun

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Aim: The aim of the present study was to investigate the association between the length of the treatment period and the cumulative dose of pegylated interferon alpha-2b (peg-IFN alpha-2b) plus ribavirin (RBV) and their effectiveness in the treatment of chronic hepatitis C. Methods: Seven hundred and fifteen patients received peg-IFN alpha-2b plus RBV treatment for 48 weeks and 24 weeks for genotypes 1 (n = 586) and 2 (n = 129), respectively. Results: Sustained virological responses (SVR), defined as serum hepatitis C virus (HCV)-RNA undetectable at 24 weeks after the end of treatment, were 42.4% and 74.4% in genotypes 1 and 2, respectively, on an intention-to-treat analysis. SVR significantly increased with treatment length (4.7%, 36.4%, and 51.8% for < 24 weeks, 24-47 weeks, and 48 weeks, respectively, for genotype 1; and 28.6%, 57.1%, 78.3% for < 12 weeks, 12-23 weeks, and 24 weeks, respectively, for genotype 2). SVR significantly increased with total cumulative treatment dose (21.1%, 36.5%, and 52.9% with < 60%, 60-79%, and ≥ 80% in peg-IFN dose; 29.6%, 51.1%, and 59.2% with < 60%, 60-79%, and ≥ 80% in RBV dose) in genotype 1, although it did not differ significantly for genotype 2. Conclusions: In peg-IFN alpha-2b plus RBV treatment for chronic hepatitis C, it is important to complete the target length of treatment and to continue the target dosage to achieve SVR, especially for genotype 1 patients.

AB - Aim: The aim of the present study was to investigate the association between the length of the treatment period and the cumulative dose of pegylated interferon alpha-2b (peg-IFN alpha-2b) plus ribavirin (RBV) and their effectiveness in the treatment of chronic hepatitis C. Methods: Seven hundred and fifteen patients received peg-IFN alpha-2b plus RBV treatment for 48 weeks and 24 weeks for genotypes 1 (n = 586) and 2 (n = 129), respectively. Results: Sustained virological responses (SVR), defined as serum hepatitis C virus (HCV)-RNA undetectable at 24 weeks after the end of treatment, were 42.4% and 74.4% in genotypes 1 and 2, respectively, on an intention-to-treat analysis. SVR significantly increased with treatment length (4.7%, 36.4%, and 51.8% for < 24 weeks, 24-47 weeks, and 48 weeks, respectively, for genotype 1; and 28.6%, 57.1%, 78.3% for < 12 weeks, 12-23 weeks, and 24 weeks, respectively, for genotype 2). SVR significantly increased with total cumulative treatment dose (21.1%, 36.5%, and 52.9% with < 60%, 60-79%, and ≥ 80% in peg-IFN dose; 29.6%, 51.1%, and 59.2% with < 60%, 60-79%, and ≥ 80% in RBV dose) in genotype 1, although it did not differ significantly for genotype 2. Conclusions: In peg-IFN alpha-2b plus RBV treatment for chronic hepatitis C, it is important to complete the target length of treatment and to continue the target dosage to achieve SVR, especially for genotype 1 patients.

UR - http://www.scopus.com/inward/record.url?scp=47649095345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47649095345&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2008.05319.x

DO - 10.1111/j.1440-1746.2008.05319.x

M3 - Article

VL - 23

SP - 1094

EP - 1104

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 7 PT1

ER -